

Clinical Characteristics and Short-Term Outcomes of Severe Patients with COVID-19 in Wuhan, China

Xiaobo Feng^{1#}, Peiyun Li^{2#}, Liang Ma^{1#}, Hang Liang¹, Jie Lei¹, Wenqiang Li¹, Kun Wang¹,
Yu Song¹, Shuai Li¹, Wei Yang^{3,4*}, Cao Yang^{1*},

1. Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
2. Department of Clinical Nutrition, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.
3. Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, Tongji Medical College, Huazhong University of Science and Technology, Hangkong Road 13, 430030, Wuhan, China.
4. Department of Nutrition and Food Hygiene and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Hangkong Road 13, 430030, Wuhan, China.

#: Xiaobo Feng, Peiyun Li and Liang Ma share contribution equally.

Dr. Cao Yang and Dr. Wei Yang are corresponding authors and to whom correspondence should be addressed:

Dr. Cao Yang, MD, Professor, Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Tel.: +86 27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

85351626; Fax: +86 27 85351626, E-mail address: caoyangunion@hust.edu.cn.

Dr. Wei Yang, PhD, Associate Professor, Department of Nutrition and Food Hygiene and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, 430030, China
Tel.: +86 27 83650522; Fax: +86 27 83650522, E-mail address: yw8278@hotmail.com or yw8278@hust.edu.cn

Abstract

Objective. A novel pneumonia (COVID-19) which is sweeping the globe was started in December, 2019, in Wuhan, China. Most deaths occurred in severe and critically cases, but information on prognostic risk factors for severe ill patients is incomplete. Further research is urgently needed to guide clinicians, so we prospectively evaluate the clinical outcomes of 114 severe ill patients with COVID-19 for short-term in the Union Hospital in Wuhan, China.

Methods. In this single-centered, prospective and observational study, we enrolled 114 severe ill patients with confirmed COVID-19 from Jan 23, 2020 to February 22, 2020. Epidemiological, demographic and laboratory information were collected at baseline, data on treatment and outcome were collected until the day of death or discharge or for the first 28 days after severe ill diagnosis, whichever was shorter. Univariate and multivariate Cox proportional hazard models were used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of poor outcome.

Results. Among enrolled 114 patients, 94 (82.5%) had good outcome while 20 (17.5%) had poor outcome. No significant differences were showed in age, gender and the prevalence of coexisting disorders between outcome groups. Results of multivariate Cox analyses indicated that higher levels of oxygen saturation (HR, 0.123; 95% CI, 0.041-0.369), albumin (HR, 0.060; 95% CI, 0.008-0.460) and arterial partial pressure of oxygen (HR, 0.321; 95% CI, 0.106-0.973) were associated with decreased risk of developing poor outcome within 28 days. In the other hand, higher levels of leucocytes (HR, 5.575; 95% CI, 2.080-14.943), neutrophils (HR, 2.566; 95% CI, 1.022-6.443), total bilirubin (HR, 6.171; 95% CI, 2.458-15.496), globulin (HR, 2.526; 95% CI, 1.027-6.211), blood urea nitrogen (HR, 5.640; 95%

CI, 2.193-14.509), creatine kinase-MB (HR, 3.032; 95% CI, 1.203-7.644), lactate dehydrogenase (HR, 4.607; 95% CI, 1.057-20.090), hypersensitive cardiac troponin I (HR, 5.023; 95% CI, 1.921-13.136), lactate concentration (HR, 15.721; 95% CI, 2.099-117.777), Interleukin-10 (HR, 3.551; 95% CI, 1.280-9.857) and C-reactive protein (HR, 5.275; 95% CI, 1.517-18.344) were associated with increased risk of poor outcome development. We also found that traditional Chinese medicine can significantly improve the patient's condition, which is conducive to the transformation from severe to mild.

Conclusion. In summary, we firstly reported this single-centered, prospective and observational study for short-term outcome in severe patients with COVID-19. We found that cytokine storm and uncontrolled inflammation responses, liver, kidney, cardiac dysfunction may play important roles in final outcome of severe ill patients with COVID-19. Our study will provide clinicians to be benefit to rapidly estimate the likelihood risk of short-term poor outcome for severe patients.

Introduction

An outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), centered in Wuhan, Hubei province, in December 2019.[1] It has rapidly spread to other cities and countries outside Wuhan and has become a global health crisis. As the disease progresses, more and more characteristics about the disease are known to us. Up to now, there are still no specific drugs, mainly supporting treatment in clinic. A large number of studies have shown that the main symptom of this disease was fever, cough and dyspnea.[2-5] Some articles have described the disease in details. Huang et al described epidemiological, clinical, laboratory, and radiological characteristics, treatment, and outcomes of 41 patients that were first group admitted hospital patients and diagnosed with SARS-CoV-2 infection, and they also compared the clinical characteristic between intensive care unit (ICU) and non-ICU patients.[2] Yang et al made a detailed analysis about the patients with critically ill with SARS-CoV-2 infection.[5] Jin et al described the characteristics of 74 cases of coronavirus infected disease 2019 (COVID-19) with gastrointestinal symptoms and proposed that non-classical symptoms have been overlooked, posing a threat to the public.[6] Wu et al discussed that older people (≥ 65 years old) with greater risk of development of acute respiratory distress syndrome (ARDS) and death.[7] Guo et al found that diabetes is a risk factor for the patients with COVID-19.[8] However, few studies took prospective study to explore the short-term outcomes of severe ill patients under current medical treatment and the risk factors that affect the short-term outcomes of severe ill patients, especially pneumonia patients with certain chronic diseases, which accounted for the majority of deaths. Here, we used a single-centered, prospective method to describe the basic clinical characteristics and short-term outcomes of severe patients in Union hospital, Wuhan,

and further explore the potential risk factors for poor outcome through Cox proportional hazard models.

Methods

Study design and participants

This is a single-center, prospective study of 114 severe patients with confirmed COVID-19 pneumonia hospitalized at Union Hospital in Wuhan, China, which is a designated hospital to treat patients with COVID-19. We continuously enrolled patients from January 23, 2020 to February 22, 2020, who had been diagnosed with COVID-19, according to WHO interim guidance. Based on the Diagnosis and Treatment Scheme for SARS- CoV-2 of Chinese (The Seven Edition), severe patients were diagnosed if one or more following criteria were met: dyspnoea with respiratory rate (RR) ≥ 30 times/min, resting finger oxygen saturation $\leq 93\%$, artery PaO₂ /FiO₂ ≤ 300 mm Hg (1 mm Hg=0.133 kPa). This study was approved by the Ethics Commission of Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology. Written informed consent was waived for the emergency of this infectious diseases.

Data collection

Data on clinical characteristics were collected by using a case record form modified from the standardized International Severe Acute Respiratory and Emerging Infection Consortium case report forms. Epidemiological and demographic information including age, sex, coexisting disorders were also collected. The baseline laboratory indices and radiographic results were obtained from clinical electronic medical records. Moreover, the treatment and outcome data

were collected until the day of death or discharge or for the first 28 days after severe ill diagnosis, whichever was shorter. All missing or vague data, direct communications with patients and their families. All data were finally checked by two physicians (Xiaobo Feng and Liang Ma) and a third researcher (Wei Yang) adjudicated any difference in interpretation between the two primary reviewers.

Outcomes

Clinical outcomes of 28 days' consecutive observations of severe patients were divided into two categories, including good outcome (discharge, non-severe or ventilator free) and poor outcome (mechanically ventilated or dead). The criteria of discharge including the temperature returned to normal for more than 3 days ($T < 37.3^{\circ}\text{C}$), respiratory symptoms were improved significantly, pulmonary imaging showed significant improvement in acute exudative lesions and nucleic acid test was negative for respiratory tract specimens such as sputum and nasopharyngeal swab for two consecutive times (at least 24 hours after sampling). Non-severe mean mild type which is defined as having slight clinical symptoms without pneumonia on radiography.

Statistics

Continuous variables were expressed as means \pm SDs if normally distributed and medians (IQRs) if skewed distributed while categorical variables were summarized as number (%). Differences of characteristics between outcome groups were assessed using student's *t* test or Mann-Whitney U test for continuous variables, and chi-square test for categorical variables.

In addition, univariate and multivariate Cox proportional hazard models were used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of poor outcome in severe patients with COVID-19. The candidate risk factors included demographic and epidemiological characteristics, as well as some laboratory indices. We determined the cut points of levels according to normal range, actual distribution and clinical significance of each index. Adjustment were made for potential confounders including age and sex. For risk factors identified in Cox analyses, we used restricted cubic spline model to further explore the potential dose-response relationship between factors and poor outcome risk. The referent (HR = 1) was set according to the cut point in Cox analyses. $P < 0.05$ was considered statistically significant. All data were analyzed by SPSS (23.0 IBM SPSS).

Results

Clinical Outcomes

A total of 114 patients with COVID-19 were enrolled in this study. At 28 days after severe ill diagnosis, 94 patients were considered as had good outcome while 20 patients had poor outcome. As shown in Figure 1, 51 (45%) patients were alive and discharge, 39 (34%) turned to non-severe ill, 4 (3%) remained severe status and ventilator free, 11 (10%) were alive but still ventilated and 9 (8%) patients had died.

Demographics and Characteristics

General demographic and epidemiological characteristics of all enrolled patients were summarized in Table 1. The median age was 63.96 ± 13.41 years, and 58 (50.9%) were older

than 65 years. Among the patients, 71 (62.3%) were male, 89 (78.1%) have chronic medical illness and the most coexisting disorders were hypertension 62 (54.4%), diabetes 39 (34.2%) and cardiovascular diseases 31 (27.2%). No significant differences were showed in such characteristics between outcome groups ($P \geq 0.05$ for all). Table 2 displayed the clinical characteristics of the patients. The duration period from onset of symptoms to diagnosis with COVID-19 and severe ill was 4.0 (2.0-7.0) days and 10.0 (6.0-14.3) days, respectively. For 114 patients, the most common symptoms at initial were fever 78 (68.4%), cough 49 (43.0%), chest tightness 34 (29.8%), fatigue 30 (26.3%). Other symptoms including shortness of breath 18 (15.8%), anorexia 12 (10.5%), chill 12 (10.5%), myalgia 10 (8.8%), sputum 9 (7.9%), headache 8 (7.0%), diarrhea 8 (7.0%), chest pain 3 (2.6%), palpitation 3 (2.6%), stomachache 3 (2.6%), nausea 3 (2.6%), sore throat 2 (1.8%) were relatively rare. As for Oxygen saturation, patients in poor outcome group had significantly lower levels than that in good outcome group [median (IQR): 91 (90-93) % in good outcome group, 81 (74-88) % in bad outcome group, $P < 0.001$].

Laboratory findings and CT scans

Regarding to 114 severe patients, many laboratory indicators differed significantly between outcome groups (Table 3). Compare with good outcome group, the absolute counts of neutrophils 6.25 (4.69-9.20) vs. 3.48 (2.54-5.23), c-reactive protein 102.15 (78.07-122.90) vs. 48.95 (15.08-83.98), D dimer 2.10 (1.22-3.07) vs. 0.96 (0.41-1.78), total bilirubin 19.20 (9.25-33.05) vs. 11.05 (8.53-14.05), blood urea nitrogen 9.02 (5.26-11.30) vs. 4.11 (3.11-5.04), creatine kinase 151.50 (50.50-218.50) vs. 62.00 (46.75-110.50), lactate dehydrogenase

638.00 (436.00-923.00) vs. 259.50 (213.75-382.50), hypersensitive cardiac troponin I 60.70 (18.48-298.98) vs. 4.10 (1.70-10.83), ferritin 679.00 (573.90-993.15) vs. 321.80 (231.00-532.88), IL6 76.10 (19.05-192.88) vs. 21.23 (7.23-47.61), IL10 6.59 (4.58-11.78) vs. 4.64 (3.65-6.18) were significantly higher in poor outcome. Besides, total protein 60.40 (56.78-64.05) vs. 63.80 (59.33-68.50), PaO₂ 68.15 (49.00-77.75) vs. 81.00 (74.75-89.00) were significantly lower in poor outcome group. For chest X- ray/CT, 107 (93.9) patients had Ground-glass opacity. These data indicated that the uncontrolled inflammation responses, infection, liver and kidney dysfunction and hypoxia may contribute to a poor outcome of COVID-19.

Complications and treatments

The severe patients with COVID-19 had complications of acute liver injury, ARDS, acute kidney injury, arrhythmia, acute myocardial injury, DIC, rhabdomyolysis, septic shock and among them, nobody had septic shock in good outcome group. Otherwise, in poor outcome group, all patients had ARDS. Acute myocardial injury, acute kidney injury, arrhythmia, rhabdomyolysis, DIC were significantly higher than their counterparts of 13.8 %, 22.3 %, 17.0%, 2.1% and 2.1% in patients with COVID-19 in good outcome group, respectively. All 114 patients with COVID-19 were treated with antibiotics and high flow nasal cannula, 25 (21.9%) with non-invasive mechanical ventilation and 22 (19.3%) with invasive mechanical ventilation treatment. Six (5.3%) patients were treated with extracorporeal membrane oxygenation (ECMO) and all of them end up with poor outcome. Almost all [113 (99.1%)] patients received antiviral treatment including the arbidol hydrochloride capsules (0.2 g three

times daily), lopinavir and ribavirin (500 mg two times daily) via the oral route. Furthermore, as many as 41.2% patients received glucocorticoid therapy. Sixty-four (56.1%) patients received immunoglobulin treatment, 49 (43.0%) patients were treated with parenteral nutrition, the percentage was higher in poor outcome group than in good outcome group [20 (100.0%) vs. 29 (30.9%)]. Two patients (1.8 %) were treated with renal replacement therapy, and 20 (17.5%) with vasoconstrictive agents and it was higher than in good outcome group [19 (95.0%) vs. 1 (1.1%)]. All 20 poor outcome patients were transferred to the ICU, which was significantly higher than that of 29 (25.4%) in the good outcome group.

Prediction of risk factors for severe COVID-19 in poor outcome group

Table 5-6 displayed the results of univariate and multivariate Cox analyses of potential factors for short-term outcomes in severe patients with COVID-19. Our results indicated that, for severe patients, higher levels of oxygen saturation (HR, 0.123; 95% CI, 0.041-0.369), albumin (HR, 0.060; 95% CI, 0.008-0.460) and arterial partial pressure of oxygen (HR, 0.321; 95% CI, 0.106-0.973) were associated with decreased risk of developing poor outcome within 28 days. In the other hand, higher levels of leucocytes (HR, 5.575; 95% CI, 2.080-14.943), neutrophils (HR, 2.566; 95% CI, 1.022-6.443), total bilirubin (HR, 6.171; 95% CI, 2.458-15.496), globulin (HR, 2.526; 95% CI, 1.027-6.211), blood urea nitrogen (HR, 5.640; 95% CI, 2.193-14.509), creatine kinase-MB (HR, 3.032; 95% CI, 1.203-7.644), lactate dehydrogenase (HR, 4.607; 95% CI, 1.057-20.090), hypersensitive cardiac troponin I (HR, 5.023; 95% CI, 1.921-13.136), lactate concentration (HR, 15.721; 95% CI, 2.099-117.777), Interleukin-10 (HR, 3.551; 95% CI, 1.280-9.857) and C-reactive protein (HR, 5.275; 95% CI,

1.517-18.344) were associated with increased risk of poor outcome development. For all the factors analyzed above, increased concentration of lactate (≥ 1.6 mmol/L) and total bilirubin (≥ 19.0 μ mol/L) might be the most important predictors of poor outcome in the early stage. Furthermore, we found that there was a nonlinear dose-response relationship between ten indices and poor outcome risk, which is depicted in Figure 2.

Discussion

SARS-CoV-2 has now spread globally and seriously threaten the human health.

Demographics and Characteristics of COVID-19 has been gradually investigated and explored by many scientists. Studies had shown that 20% of COVID-19 patients developed to critically disease due to hypoxia or respiratory failure, among them, 5% needed to treat in intensive care unit and 15% required oxygen and essential care. This suggests that this is particularly important in understanding this part of the patient.[9] [10] Recently, Dong et al found that children, in particular, infants developed into severe outcomes. This indicated that patients of any age could develop to severe illness.[11] Feng et al found that severe and critical patients with the typical characteristics of multiple organ and immune function dysfunction. They also found that older people with age (≥ 75 years) was a risk factor for mortality.[12] With the increase number of asymptomatic infectious patients, take measures to detect and isolate early are especially important. In our study, we take a short-term method to prospectively study the reported the epidemiology and risk factors of 114 severe patients with COVID-19 from Union hospital, Hubei province. To our knowledge, this is the first report to describes the severe patients with COVID-19 during a short-term observation and predicted some risk factors for final outcome. In our study, the average age of severe patients

were 63.96 ± 13.41 years and 58 (50.9%) were older than 65 years, the patients are older than in other studies.[5, 13, 14] We also found that 78 (68.4%) of 114 patients were had fever at initial, this was in accordance with previous studies, which fever is the one of the most common symptom in patients who had COVID-19.[5, 14-16] But, 36 (31.6%) of 114 severe patients who were had not fever at the beginning of illness, therefore, other clinical manifestations should be concerned. In recently, Jin et al found that attention should also pay on people who had gastrointestinal symptoms.[6] Mao et al indicated that patients with Neurologic manifestations, clinicians should suspect COVID-19.[14]

According to results from laboratory tests, poor outcome group had lower lymphocytes than good outcome group [0.67 (0.43-0.89) vs. 0.92 (0.70-1.43)]. As is known to all, lymphocytes are the main fighting force against the virus, we suspected that SARS-CoV-2 viral damages on the lymphocyte and causes its reduction.[17] Chen et al found that severe lymphopenia were persistent and more in dead patients than recovered patients and they suggested that a lymphopenia may associated with poor outcome.[18] Tan et al demonstrated a oppose result that lymphopenia is an effective indicator for the severity of patients with COVID-19.[19] CD8⁺ T cells were significantly lower in poor outcome group. Chen et al indicated that the SARS-CoV-2 infection may affect CD4⁺ and CD8⁺ T lymphocytes cells particularly and argue that this is potential correlation with COVID-19 severity.[20] In addition, markedly higher concentrations of cardiac troponin I, creatine kinase, lactate dehydrogenase could be observed in poor outcome group than in their counterpart. Most notably, patients who had poor outcome may develop pulmonary and extra-pulmonary organ damage, including septic shock, acute respiratory distress syndrome, acute kidney injury, acute cardiac injury as well

as disseminated intravascular coagulation. Fatality risk of COVID-19 patients with or without history of previous cardiovascular disease may be acute cardiac injury and heart failure.[18] Costanza Emanuelli et al suggested that the COVID-19 crisis will have a longer term residual repercussions on the cardiovascular system.[21] This suggestion that the cardiac injury also requires special attention. In our study, we also found that lactate concentration was higher in poor outcome than their counterpart. As with all known, lactate is generally the end product of energy through anaerobic metabolism, and the elevation of lactate level is mainly caused by the increase of blood oxygen deficiency and anaerobic metabolism, this result is consistent with the lower oxygen saturation in poor group, this indicated that lactate level was an important predictors of poor outcome in the early stage. In addition, total bilirubin was also an important predictor of poor outcome in the early stage. Qi recommend that dynamic monitor the liver function of patients is necessary.[22] Cai conclude that patients with abnormal liver function may had higher risks to progress to severe disease.[23] Due to the “cytokine storm” also observed in poor outcome group, 19 (95.0%) of these patients were given glucocorticoid therapy. Wu et al previously found that the administration of methylprednisolone may have reduced the risk of death in patients with ARDS.[7] To our surprise, most of the severe patients treated with Traditional Chinese medicine (TCM) were eventually converted to good outcome, indicated this important effort on COVID-19. A large of clinical practice results indicated that TCM shows significant role in the patients with COVID-19. For the severe patients in the treatment of TCM, the mean length in hospital and the time of nucleic acid turning negative has been shortened by more than 2 days.[24] Yao et al. and Lu et al. analyzed the effect of Lian Hua Qing Wen Capsule in treatment of COVID-

19 patients and they found that this TCM could markedly relieve fever and cough and can promote the recovery.[25] Besides, the comprehensive evaluation and scientific research should be carried out on the effect of TCM on COVID-19.

Meantime, the risk factors related to the poor outcome included uncontrolled inflammation responses, infection, liver and kidney, cardiac dysfunction and hypoxia. The pathogenesis of COVID-19 is still studying. Cytokine storm and uncontrolled inflammation responses are thought to play important roles in the outcome of COVID-19.[26-30] External stimuli resulted to excessive immune response and the pathogenesis of the cytokine storm is complex which led to rapid disease progresses and high mortality. The inflammatory cytokine storm is closely correlated to the development and progression of ARDS.[31] Neutrophils play important role in chemokines and cytokines.[32] In our study, poor outcome had significantly higher neutrophil counts than good outcome group, which may lead to the cytokine storm. In addition, CD8⁺ T cells were significantly lower in poor outcome group. These results mean the important roles of CD8 T cells in COVID-19. Studies had shown that T-cell could inhibit the over-activation of innate immunity.[33] T cells can help to clear the SARS-CoV, and low T-cell response can result in pathological changes in mice with SARS-CoV.[34] The relevant mechanisms need to be further studied.

This study has some limitations. First, owing to the limited number of cases, only 114 severe patients were included. Second, this study was a single-center research and a larger cohort study of severe patients with SARS-CoV-2 from other cities in China and other countries would help to further describe the clinical characteristics and predict the risk factors about this disease.

In summary, we firstly reported this single-centered, prospective, observational study for short-term in severe patients with COVID-19. We found from univariate and multivariate Cox model that cytokine storm and uncontrolled inflammation responses, liver, kidney, cardiac dysfunction may play important roles in final outcome of severe ill patients with COVID-19. This will help clinicians to diagnose and treat severe patients.

Author contributions

Cao Yang and Wei Yang designed the study and had full access to all data in the study and take responsibility for the integrity of data and the accuracy of the data analysis. Xiaobo Feng and Liang Ma contributed to data collection, literature searches, and writing of the manuscript. Xiaobo Feng and Peiyun Li had roles in data analysis and data interpretation. All authors contributed to data acquisition, clinical management, and reviewed and approved the final version of the manuscript. Xiaobo Feng, Peiyun Li and Liang Ma share first authorship and Cao Yang and Wei Yang are co-corresponding authors; the order in which they are listed was determined by workload.

Declaration of interests

We declare no competing interests.

Acknowledgments

We thank all the patients and their families involved in this study, as well as numerous

civilians working together to fight against the SARS-CoV-2.

References

- [1] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G.F. Gao, W. Tan, A Novel Coronavirus from Patients with Pneumonia in China, 2019, *New England Journal of Medicine* 382(8) (2020) 727-733.
- [2] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, *The Lancet* 395(10223) (2020) 497-506.
- [3] W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, L. Liu, H. Shan, C.L. Lei, D.S.C. Hui, B. Du, L.J. Li, G. Zeng, K.Y. Yuen, R.C. Chen, C.L. Tang, T. Wang, P.Y. Chen, J. Xiang, S.Y. Li, J.L. Wang, Z.J. Liang, Y.X. Peng, L. Wei, Y. Liu, Y.H. Hu, P. Peng, J.M. Wang, J.Y. Liu, Z. Chen, G. Li, Z.J. Zheng, S.Q. Qiu, J. Luo, C.J. Ye, S.Y. Zhu, N.S. Zhong, C. China Medical Treatment Expert Group for, Clinical Characteristics of Coronavirus Disease 2019 in China, *N Engl J Med* (2020).
- [4] X.W. Xu, X.X. Wu, X.G. Jiang, K.J. Xu, L.J. Ying, C.L. Ma, S.B. Li, H.Y. Wang, S. Zhang, H.N. Gao, J.F. Sheng, H.L. Cai, Y.Q. Qiu, L.J. Li, Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series, *BMJ* 368 (2020) m606.
- [5] X. Yang, Y. Yu, J. Xu, H. Shu, J.a. Xia, H. Liu, Y. Wu, L. Zhang, Z. Yu, M. Fang, T. Yu, Y. Wang, S. Pan, X. Zou, S. Yuan, Y. Shang, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, *The Lancet Respiratory Medicine* (2020).
- [6] X. Jin, J.S. Lian, J.H. Hu, J. Gao, L. Zheng, Y.M. Zhang, S.R. Hao, H.Y. Jia, H. Cai, X.L. Zhang, G.D. Yu, K.J. Xu, X.Y. Wang, J.Q. Gu, S.Y. Zhang, C.Y. Ye, C.L. Jin, Y.F. Lu, X. Yu, X.P. Yu, J.R. Huang, K.L. Xu, Q. Ni, C.B. Yu, B. Zhu, Y.T. Li, J. Liu, H. Zhao, X. Zhang, L. Yu, Y.Z. Guo, J.W. Su, J.J. Tao, G.J. Lang, X.X. Wu, W.R. Wu, T.T. Qv, D.R. Xiang, P. Yi, D. Shi, Y. Chen, Y. Ren, Y.Q. Qiu, L.J. Li, J. Sheng, Y. Yang, Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms, *Gut* (2020).
- [7] C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang, X. Zhou, C. Du, Y. Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu, X. Zhou, D. Chen, W. Xiong, L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng, Y. Song, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, *JAMA Intern Med* (2020).
- [8] W. Guo, M. Li, Y. Dong, H. Zhou, Z. Zhang, C. Tian, R. Qin, H. Wang, Y. Shen, K. Du, L. Zhao, H. Fan, S. Luo, D. Hu, Diabetes is a risk factor for the progression and prognosis of COVID-19, *Diabetes Metab Res Rev* (2020) e3319.
- [9] T. Baker, C.O. Schell, D.B. Petersen, H. Sawe, K. Khalid, S. Mndolo, J. Rylance, D.F. McAuley, N. Roy, J. Marshall, L. Wallis, E. Molyneux, Essential care of critical illness must not be forgotten in the COVID-19 pandemic, *The Lancet* (2020).
- [10] Z Wu, J. McGoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China., *JAMA* (2020).
- [11] H. Stower, Clinical and epidemiological characteristics of children with COVID-19, *Nat Med* (2020).
- [12] Y.F. ;, Yun Ling , Tao Bai , Y.X. ;, Jie Huang , Jian Li , Weining Xiong , Dexiang Yang , R.C. ;, F.L. ;, Yunfei Lu , Xuhui Liu , Yuqing Chen , Xin Li , Yong Li , Hanssa Dwarka Summah , Huihuang Lin , J.Y. ;, Min Zhou , H. Lu, J. Qu, COVID-

- 19 with Different Severity_ A Multi-center Study of Clinical Features, *Am J Respir Crit Care Med* (2020).
- [13] N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, Y. Wei, J.a. Xia, T. Yu, X. Zhang, L. Zhang, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, *The Lancet* 395(10223) (2020) 507-513.
- [14] L. Mao, H. Jin, M. Wang, Y. Hu, S. Chen, Q. He, J. Chang, C. Hong, Y. Zhou, D. Wang, X. Miao, Y. Li, B. Hu, Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China, *JAMA Neurol* (2020).
- [15] D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong, Y. Zhao, Y. Li, X. Wang, Z. Peng, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, *JAMA* (2020).
- [16] Z. Wang, X. Chen, Y. Lu, F. Chen, W. Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, *Biosci Trends* 14(1) (2020) 64-68.
- [17] J. Gu, E. Gong, B. Zhang, J. Zheng, Z. Gao, Y. Zhong, W. Zou, J. Zhan, S. Wang, Z. Xie, H. Zhuang, B. Wu, H. Zhong, H. Shao, W. Fang, D. Gao, F. Pei, X. Li, Z. He, D. Xu, X. Shi, V.M. Anderson, A.S. Leong, Multiple organ infection and the pathogenesis of SARS, *J Exp Med* 202(3) (2005) 415-24.
- [18] T. Chen, D. Wu, H. Chen, W. Yan, D. Yang, G. Chen, K. Ma, D. Xu, H. Yu, H. Wang, T. Wang, W. Guo, J. Chen, C. Ding, X. Zhang, J. Huang, M. Han, S. Li, X. Luo, J. Zhao, Q. Ning, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, *BMJ* 368 (2020) m1091.
- [19] L. Tan, Q. Wang, D. Zhang, J. Ding, Q. Huang, Y.Q. Tang, Q. Wang, H. Miao, Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, *Signal Transduct Target Ther* 5 (2020) 33.
- [20] G. Chen, D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, X. Zhang, H. Chen, H. Yu, X. Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S. Li, X. Luo, J. Zhao, Q. Ning, Clinical and immunological features of severe and moderate coronavirus disease 2019, *J Clin Invest* (2020).
- [21] C. Emanuelli, L. Badimon, F. Martelli, I. Potocnjak, I. Carpusca, E.L. Robinson, Y. Devaux, Call to action for the cardiovascular side of COVID-19, *Eur Heart J* (2020).
- [22] X. Qi, C. Liu, Z. Jiang, Y. Gu, G. Zhang, C. Shao, H. Yue, Z. Chen, B. Ma, D. Liu, L. Zhang, J. Wang, D. Xu, J. Lei, X. Li, H. Huang, Y. Wang, H. Liu, J. Yang, H. Pan, W. Liu, W. Wang, F. Li, S. Zou, H. Zhang, J. Dong, Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury, *J Hepatol* (2020).
- [23] Q. Cai, D. Huang, H. Yu, Z. Zhu, Z. Xia, Y. Su, Z. Li, G. Zhou, J. Gou, J. Qu, Y. Sun, Y. Liu, Q. He, J. Chen, L. Liu, L. Xu, Characteristics of Liver Tests in COVID-19 Patients, *J Hepatol* (2020).
- [24] J.L. Ren, A.H. Zhang, X.J. Wang, Traditional Chinese medicine for COVID-19 treatment, *Pharmacol Res* 155 (2020) 104743.
- [25] Y. Yang, M.S. Islam, J. Wang, Y. Li, X. Chen, Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective, *Int J Biol Sci* 16(10) (2020) 1708-1717.
- [26] S. Wan, Q. Yi, S. Fan, J. Lv, X. Zhang, L. Guo, C. Lang, Q. Xiao, K. Xiao, Z. Yi, M. Qiang, J. Xiang, B. Zhang, Y. Chen, Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), (2020).
- [27] Q. Ye, B. Wang, J. Mao, Cytokine Storm in COVID-19 and Treatment, *J Infect* (2020).
- [28] L. Chen, H.G. Liu, W. Liu, J. Liu, K. Liu, J. Shang, Y. Deng, S. Wei, Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia, *Zhonghua Jie He He Hu Xi Za Zhi* 43(3) (2020) 203-208.
- [29] P. Mehta, D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, COVID-19: consider cytokine storm syndromes and immunosuppression, *The Lancet* 395(10229) (2020) 1033-1034.
- [30] L.A. Henderson, S.W. Canna, G.S. Schulert, S. Volpi, P.Y. Lee, K.F. Kernan, R. Caricchio, S. Mahmud, M.M. Hazen,

O. Halyabar, K.J. Hoyt, J. Han, A.A. Grom, M. Gattorno, A. Ravelli, F. de Benedetti, E.M. Behrens, R.Q. Cron, P.A. Nigrovic, On the alert for cytokine storm: Immunopathology in COVID-19, *Arthritis Rheumatol* (2020).

[31] B. KL, Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury, *Curr Infect Dis Rep* 7(5) (2005) 327-8.

[32] L. TW, , Kwek TK, Tai D, Earnest A, Loo S, Singh K, Kwan KM, Chan Y, Yim CF, Bek SL, Kor AC, Yap WS, Chelliah YR, Lai YC, G. SK., Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome., *JAMA* 290(3) (2003) 374-80.

[33] K.D. Kim, J. Zhao, S. Auh, X. Yang, P. Du, H. Tang, Y.X. Fu, Adaptive immune cells temper initial innate responses, *Nat Med* 13(10) (2007) 1248-52.

[34] J. Zhao, J. Zhao, S. Perlman, T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice, *J Virol* 84(18) (2010) 9318-25.

Figure legends

Figure 1 Distribution of short-term (28 days) outcomes of severe ill patients with COVID-19 (N=114).




Figure 2 Nonlinear dose-response relationship between ten indices and poor outcome risk.

Hazard ratios (HRs) were adjusted for age and gender. Dotted lines represent the 95% CIs for the fitted trend. (A) Leucocytes ($\times 10^9$ /L), referent (HR =1): 9.5; (B) Neutrophils ($\times 10^9$ /L), referent: 6.3; (C) Total bilirubin ($\mu\text{mol/L}$), referent: 19.0; (D) Albumin, referent: 35.0 (g/L); (E) Globulin (g/L), referent: 30.0; (F) Blood urea nitrogen (mmol/L), referent: 8.2; (G) CK-MB (U/L), referent: 24.0; (H) Lactate dehydrogenase (U/L), referent: 245; (I) Hypersensitive cardiac troponin I (ng/L), referent: 26.2; (J) Lactate (mmol/L), referent: 1.6.




Table 1 Demographic and epidemiological characteristics of severe patients with COVID-19

	Total (N=114)	Good outcome (N=94)	Poor outcome (N=20)	P
Age (years)	63.96 ± 13.41	62.85 ± 13.65	69.15 ± 11.08	0.056
< 65	52 (45.6)	46 (48.9)	6 (30.0)	0.123
≥ 65	62 (54.4)	48 (51.1)	14 (70.0)	
Sex, male	71 (62.3)	58 (61.7)	13 (65.0)	0.782
Hospital infection	7 (6.1)	6 (6.4)	1 (5.0)	> 0.999
Coexisting disorders	89 (78.1)	73 (77.7)	16 (80.0)	> 0.999
Diabetes	39 (34.2)	34 (36.2)	5 (25.0)	0.339
Hypertension	62 (54.4)	50 (53.2)	12 (60.0)	0.579
Hyperlipidemia	17 (14.9)	15 (16.0)	2 (10.0)	0.739
Cardiovascular diseases	31 (27.2)	24 (25.5)	7 (35.0)	0.388
Cerebrovascular diseases	6 (5.3)	3 (3.2)	3 (15.0)	0.110
Cancer	10 (8.8)	9 (9.6)	1 (5.0)	0.825
Chronic renal diseases	6 (5.3)	4 (4.3)	2 (10.0)	0.622
Chronic liver diseases	4 (3.5)	3 (3.2)	1 (5.0)	0.543
Chronic Obstructive Pulmonary Disease	11 (9.6)	9 (9.6)	2 (10.0)	> 0.999
Neuropsychiatric disorders	3 (2.6)	2 (2.1)	1 (5.0)	0.443
History of surgery	33 (28.9)	26 (27.7)	7 (35.0)	0.511

Values are n (%) for categorical data, means ± SDs for normally distributed data, or medians (IQRs) for non-normally distributed data.

Table 2 Clinical characteristics of severe patients with COVID-19

	Total (N=114)	Good outcome (N=94)	Poor outcome (N=20)	<i>P</i>
Onset of symptom to, d				
Dignosis	4.0 (2.0-7.0)	4.0 (2.0-7.0)	4.5 (2.3-10.8)	0.517
Servious illness	10.0 (6.0-14.3)	10.0 (6.0-15.0)	8.0 (5.0-14.0)	0.540
Signs and symptoms at initial				
Fever	78 (68.4)	63 (67.0)	15 (75.0)	0.486
Chest tightness	34 (29.8)	27 (28.7)	7 (35.0)	0.577
Shortness of breath	18 (15.8)	13 (13.8)	5 (25.0)	0.365
Cough	49 (43.0)	39 (41.5)	10 (50.0)	0.485
Sputum	9 (7.9)	8 (8.5)	1 (5.0)	0.943
Fatigue	30 (26.3)	28 (29.8)	2 (10.0)	0.068
Headache	8 (7.0)	7 (7.4)	1 (5.0)	> 0.999
Mylgia	10 (8.8)	8 (8.5)	2 (10.0)	> 0.999
Chest pain	3 (2.6)	3 (3.2)	0 (0.0)	1.000
Anorexia	12 (10.5)	12 (12.8)	0 (0.0)	0.198
Chill	12 (10.5)	8 (8.5)	4 (20.0)	0.263
Stomachache	3 (2.6)	3 (3.2)	0 (0.0)	> 0.999
Diarrhea	8 (7.0)	7 (7.4)	1 (5.0)	> 0.999
Nausea	3 (2.6)	2 (2.1)	1 (5.0)	0.443
Temperature at disease onset (°C)	38.1 (36.7-38.8)	38.1 (36.7-38.7)	38.2 (37.0-39.0)	0.561
< 37.4	36 (31.6)	31 (33.0)	5 (25.0)	0.622
37.4-39.0	63 (55.3)	50 (53.2)	13 (65.0)	
> 39.0	15 (13.2)	13 (13.8)	2 (10.0)	
Signs and symptoms at hospital admission				
Fever	32 (28.1)	25 (26.6)	7 (35.0)	0.448
Chest tightness	50 (43.9)	46 (48.9)	4 (20.0)	0.018
Shortness of breath	68 (59.6)	49 (52.1)	19 (95.0)	< 0.001
Cough	9 (7.9)	7 (7.4)	2 (10.0)	> 0.999
Fatigue	43 (37.7)	37 (39.4)	6 (30.0)	0.433
Headache	6 (5.3)	6 (6.4)	0 (0.0)	0.542
Mylgia	5 (4.4)	5 (5.3)	0 (0.0)	0.585
Chest pain	3 (2.6)	3 (3.2)	0 (0.0)	> 0.999
Anorexia	18 (15.8)	16 (17.0)	2 (10.0)	0.657
Diarrhea	10 (8.8)	7 (7.4)	3 (15.0)	0.516

Nausea	2 (1.8)	2 (2.1)	0 (0.0)	> 0.999
General signs at admission				
Temperature (°C)	36.7 (36.4-37.4)	36.7 (36.4-37.3)	38.2 (37.0-39.0)	0.279
< 37.4	85 (74.6)	72 (76.6)	13 (65.0)	0.535
37.4-39.0	26 (22.8)	20 (21.3)	6 (30.0)	
> 39.0	3 (2.6)	2 (2.1)	1 (5.0)	
Heart rate (/min)	86 (78-102)	87 (78-102)	88 (78-102)	0.456
< 100	83 (72.8)	69 (73.4)	14 (70.0)	0.756
> 100	31 (27.2)	25 (26.6)	6 (30.0)	
Respiratory rate (/min)	20 (20-23)	20 (20-22)	21 (20-30)	0.122
< 20	22 (19.3)	19 (20.2)	3 (15.0)	0.760
≥ 20	92 (80.7)	75 (79.8)	17 (85.0)	
Oxygen saturation (%)	90 (88-92)	91 (90-93)	81 (74-88)	< 0.001
< 90	35 (30.7)	19 (20.2)	16 (80.0)	< 0.001
≥ 90	79 (69.3)	75 (79.8)	4 (20.0)	

Values are n (%) for categorical data, means ± SDs for normally distributed data, or medians (IQRs) for non-normally distributed data.

Table 3 Laboratory and radiographic findings at baseline of severe patients with COVID-19

	Total (N=114)	Good outcome (N=94)	Poor outcome (N=20)	P
Hematologic				
Leucocytes ($\times 10^9$ /L)	6.28 \pm 3.36	5.74 \pm 2.49	8.78 \pm 5.36	0.022
Neutrophils ($\times 10^9$ /L)	3.88 (2.65-5.81)	3.48 (2.54-5.23)	6.25 (4.69-9.20)	< 0.001
Lymphocytes ($\times 10^9$ /L)	0.87 (0.65-1.31)	0.92 (0.70-1.43)	0.67 (0.43-0.89)	0.001
Monocytes ($\times 10^9$ /L)	0.44 (0.30-0.59)	0.48 (0.33-0.61)	0.34 (0.22-0.40)	0.009
Platelets ($\times 10^9$ /L)	192.00 (140.74-269.75)	205.00 (142.75-272.50)	165.00 (138.25-218.00)	0.160
Haemoglobin (g/L)	122.04 \pm 17.78	122.65 \pm 16.75	119.15 \pm 22.29	0.427
CD4+ T cells (%)	43.54 (36.45-53.41)	44.98 (36.53-53.20)	39.95 (31.46-57.32)	0.687
CD8+ T cells (%)	21.53 (16.48-28.55)	22.11 (17.61-29.95)	17.90 (14.00-23.45)	0.025
Coagulation function				
Prothrombin time (s)	13.5 (12.8-14.3)	13.40 (12.70-14.23)	14.25 (12.93-15.28)	0.072
Activated partial thromboplastin time (s)	38.00 (35.18-41.53)	38.00 (35.10-41.43)	38.45 (35.45-43.98)	0.398
Fibrinogen (g/L)	4.98 \pm 1.48	5.05 \pm 1.43	4.66 \pm 1.67	0.282
Thrombin time (s)	17.35 (16.58-18.30)	17.35 (16.77-18.15)	17.20 (15.35-19.18)	0.467
D-dimer (mg/L)	1.06 (0.51-2.10)	0.96 (0.41-1.78)	2.10 (1.22-3.07)	0.005
Biochemical				
Alanine aminotransferase (U/L)	45.50 (26.00-74.25)	44.50 (25.75-72.50)	49.00 (29.25-80.25)	0.427
Aspartate aminotransferase (U/L)	39.50 (26.75-64.50)	38.50 (26.00-57.25)	44.00 (29.50-114.75)	0.197
Total bilirubin (μ mol/L)	11.35 (8.93-16.15)	11.05 (8.53-14.05)	19.20 (9.25-33.05)	0.024
Total protein (g/L)	63.10 (58.48-67.70)	63.80 (59.33-68.50)	60.40 (56.78-64.05)	0.015
Albumin (g/L)	34.65 (30.350-38.60)	35.80 (31.85-39.10)	30.05 (27.10-32.65)	< 0.001
Globulin (g/L)	29.15 (25.70-31.65)	28.95 (25.68-30.78)	30.35 (29.63-35.50)	0.057

Prealbumin (mg/L)	120 (90-153)	120 (90-151)	93 (82-181)	0.145
Blood urea nitrogen (mmol/L)	4.39 (3.27-6.13)	4.11 (3.11-5.04)	9.02 (5.26-11.30)	< 0.001
Creatinine (μ mol/L)	74.35 (60.00-87.85)	74.35 (60.28-86.38)	71.80 (53.70-95.60)	0.636
Creatine kinase (U/L)	66.50 (46.75-133.50)	62.00 (46.75-110.50)	151.50 (50.50-218.50)	0.046
Creatine kinase-MB (U/L)	17.00 (14.00-23.00)	17.00 (14.00-22.00)	19.50 (13.00-31.75)	0.234
Lactate dehydrogenase (U/L)	286.00 (223.75-452.25)	259.50 (213.75-382.50)	638.00 (436.00-923.00)	< 0.001
Hypersensitive cardiac troponin I (ng/L)	5.70 (2.10-19.05)	4.10 (1.70-10.83)	60.70 (18.48-298.98)	< 0.001
Glucose (mmol/L)	6.20 (5.20-8.31)	6.13 (5.16-7.63)	8.26 (5.81-13.42)	0.013
Serum potassium (mmol/L)	4.03 (3.70-4.50)	4.07 (3.72-4.51)	3.97 (3.59-4.36)	0.344
Serum sodium (mmol/L)	138.85 (136.30-142.00)	138.20 (136.00-141.68)	142.40 (138.85-146.93)	0.001
Serum calcium (mmol/L)	2.15 \pm 0.18	2.17 \pm 0.16	2.04 \pm 0.20	0.003
Serum phosphorus (mmol/L)	1.00 (0.88-1.11)	1.00 (0.89-1.11)	0.95 (0.73-1.12)	0.381
Serum chlorine (mmol/L)	100.48 \pm 5.10	100.03 \pm 4.45	102.61 \pm 7.20	0.137
Lactate concentration (mmol/L)	1.60 (1.38-1.80)	1.50 (1.30-1.70)	2.10 (1.70-2.40)	< 0.001
Positive Urinary protein, n	47 (41.2)	33 (35.1)	14 (70.0)	0.004
Positive Urinary glucose, n	8 (7.0)	7 (7.4)	1 (5.0)	> 0.999
Positive urinary occult blood, n	31 (27.2)	21 (22.3)	10 (50.0)	0.012
Blood gas characteristics				
pH	7.39 (7.36-7.42)	7.38 (7.36-7.42)	7.41 (7.31-7.46)	0.636
Arterial partial pressure of oxygen (mm Hg)	79.00 (70.00-88.00)	81.00 (74.75-89.00)	68.15 (49.00-77.75)	< 0.001
Arterial partial pressure of carbon dioxide (mm Hg)	43.00 (38.00-46.00)	42.80 (38.00-45.00)	45.50 (35.60-57.00)	0.198
Infection-related biomarkers				
Interleukin 2 (pg/mL)	2.70 (2.43-3.04)	2.70 (2.47-3.02)	2.69 (2.41-3.60)	0.991

Interleukin 4 (pg/mL)	2.16 (1.85-2.60)	2.16 (1.89-2.52)	2.21 (1.68-3.50)	0.729
Interleukin 6 (pg/mL)	23.28 (8.31-54.23)	21.23 (7.23-47.61)	76.10 (19.05-192.88)	0.002
Interleukin 10 (pg/mL)	4.91 (3.92-6.74)	4.64 (3.65-6.18)	6.59 (4.58-11.78)	0.001
Tumour necrosis factor- α (pg/mL)	2.63 (2.11-4.80)	2.63 (2.11-4.80)	2.67 (2.07-4.66)	0.838
Interferon- γ (pg/mL)	2.50 (1.96-3.20)	2.46 (1.96-3.20)	2.58 (1.89-3.49)	0.571
C-reactive protein (mg/L)	67.95 (20.50-103.25)	48.95 (15.08-83.98)	102.15 (78.07-122.90)	< 0.001
Ferritin (ng/mL)	390.60 (261.70-721.00)	321.80 (231.00-532.88)	679.00 (573.90-993.15)	0.001
IgM, n	60 (68.2)	52 (69.3)	8 (61.5)	0.748
IgG, n	88 (100.0)	75 (100.0)	13 (100.0)	NA
Chest X- ray/CT findings				
Ground-glass opacity	107 (93.9)	87 (92.6)	20 (100.0)	0.351
Unilateral pneumonia	11 (9.6)	11 (11.7)	0 (0.0)	0.208
Bilateral pneumonia	102 (89.5)	82 (87.2)	20 (100.0)	0.122
Interstitial abnormalities	21 (18.4)	15 (16.0)	6 (30.0)	0.200

Data are n (%), means \pm SDs or medians (IQRs) when appropriate.

Table 4 Complications and treatments of severe patients with COVID-19

	Total (N=114)	Good outcome (N=94)	Poor outcome (N=20)	P
Complications				
Shock	8 (7.0)	0 (0.0)	8 (40.0)	< 0.001
Acute respiratory distress syndrome	41 (36.0)	21 (22.3)	20 (100.0)	< 0.001
Acute renal injury	35 (30.7)	21 (22.3)	14 (70.0)	< 0.001
Acute myocardial injury	28 (24.6)	13 (13.8)	15 (75.0)	< 0.001
Acute liver function injury	69 (60.5)	57 (60.6)	12 (60.0)	0.958
Arrhythmia	31 (27.2)	16 (17.0)	15 (75.0)	< 0.001
Rhabdomyolysis	11 (9.6)	2 (2.1)	9 (45.0)	< 0.001
Disseminated intravascular coagulation	15 (13.2)	2 (2.1)	13 (65.0)	< 0.001
Treatment				
Antibiotic treatment	114 (100.0)	94 (100.0)	20 (100.0)	NA
Anticoronavirus treatment	113 (99.1)	93 (98.9)	20 (100.0)	> 0.999
Glucocorticoids	47 (41.2)	28 (29.8)	19 (95.0)	< 0.001
Oxygen therapy	114 (100.0)	94 (100.0)	20 (100.0)	NA
Immunoglobulin	64 (56.1)	45 (47.9)	19 (95.0)	< 0.001
Parenteral nutrition	49 (43.0)	29 (30.9)	20 (100.0)	< 0.001
Admission to intensive care unit	29 (25.4)	9 (9.6)	20 (100.0)	< 0.001
Noninvasive ventilation	25 (21.9)	13 (13.8)	12 (60.0)	< 0.001
Invasive mechanical ventilation	22 (19.3)	4 (4.3)	18 (90.0)	< 0.001
Extracorporeal membrane oxygenation	6 (5.3)	0 (0.0)	6 (30.0)	< 0.001
Vasoconstrictive agents	20 (17.5)	1 (1.1)	19 (95.0)	< 0.001
Renal replacement therapy	2 (1.8)	0 (0.0)	2 (10.0)	0.029
Traditional Chinese medicine	86 (75.4)	77 (81.9)	9 (45.0)	0.001
Trastuzumab	13 (11.4)	12 (12.8)	1 (5.0)	0.459
Infusions of blood plasma	4 (3.5)	2 (2.1)	2 (10.0)	0.141
Onset of severe illness to, d*				
1 st for RT-PCR (-)	14.0 (11.0-18.0)	14.0 (10.0-18.0)	19.0 (15.5-24.0)	<0.001
2 nd for RT-PCR (-)	17.5 (14.0-22.0)	17.0 (14.0-21.5)	24.0 (22.0-27.5)	<0.001

Data are n (%) or medians (IQRs) when appropriate.

*Data available for 98 patients.

Table 5 Univariate and multivariate analyses of potential factors (demographic and epidemiologic) predicting poor outcome

Factors	Level	Crude HR (95% CI)	<i>P</i>	Adjusted HR (95% CI)*	<i>P</i>
Age (years)	≥ 65 v.s. < 65	2.192 (0.842-5.708)	0.108	2.184 (0.839-5.687)	0.110
Sex	Female v.s. Male	0.772 (0.308-1.937)	0.581	0.732 (0.292-1.838)	0.507
Coexisting disorders	Yes v.s. No	1.154 (0.386-3.453)	0.797	0.692 (0.207-2.313)	0.550
Diabetes	Yes v.s. No	0.706 (0.257-1.945)	0.380	0.622 (0.224-1.728)	0.363
Hypertension	Yes v.s. No	1.122 (0.458-2.747)	0.801	0.960 (0.386-2.384)	0.929
Hyperlipidemia	Yes v.s. No	0.677 (0.157-2.919)	0.601	0.729 (0.168-3.167)	0.673
Cardiovascular diseases	Yes v.s. No	1.601 (0.638-4.015)	0.316	1.062 (0.380-2.970)	0.908
Cerebrovascular diseases	Yes v.s. No	3.327 (0.975-11.356)	0.055	2.326 (0.612-8.848)	0.216
Cancer	Yes v.s. No	0.536 (0.072-4.004)	0.543	0.410 (0.054-3.103)	0.388
Chronic renal diseases	Yes v.s. No	3.678 (0.835-16.202)	0.085	3.437 (0.764-15.465)	0.108
Chronic liver diseases	Yes v.s. No	1.433 (0.192-10.707)	0.726	0.997 (0.128-7.760)	0.997
Chronic Obstructive Pulmonary Disease	Yes v.s. No	0.991 (0.230-4.272)	0.990	0.642 (0.139-2.955)	0.569
Neuropsychiatric disorders	Yes v.s. No	1.186 (0.158-8.894)	0.868	0.734 (0.094-5.741)	0.768
History of surgery	Yes v.s. No	1.168 (0.466-2.930)	0.740	1.041 (0.413-2.623)	0.932
Temperature at disease onset (°C)	37.4-39.0 v.s. < 37.4	1.514 (0.540-4.248)	0.430	1.844 (0.638-5.326)	0.258
	> 39.0 v.s. < 37.4	1.036 (0.201-5.342)	0.966	2.714 (0.348-21.190)	0.622
Temperature at admission (°C)	37.4-39.0 v.s. < 37.4	1.476 (0.561-3.885)	0.430	1.721 (0.646-4.580)	0.277
	> 39.0 v.s. < 37.4	2.630 (0.343-20.167)	0.352	2.714 (0.348-21.190)	0.341
Respiratory rate (/min)	≥ 20 v.s. < 20	1.357 (0.398-4.629)	0.626	1.316 (0.385-4.502)	0.662
Oxygen saturation (%)	≥ 90 v.s. < 90	0.131 (0.044-0.394)	< 0.001	0.123 (0.041-0.369)	< 0.001

*Adjustments were made for age and sex.

Table 6 Univariate and multivariate analyses of potential factors (laboratory indexes) predicting poor outcome

Factors	Normal range	Level [†]	Crude HR (95% CI)	<i>P</i>	Adjusted HR (95% CI)*	<i>P</i>
Hematologic						
Leucocytes ($\times 10^9$ /L)	3.5-9.5	≥ 9.5 v.s. < 9.5	4.634 (1.840-11.669)	0.001	5.575 (2.080-14.943)	0.001
Neutrophils ($\times 10^9$ /L)	1.8-6.3	≥ 6.3 v.s. < 6.3	2.663 (1.102-6.433)	0.030	2.566 (1.022-6.443)	0.045
Lymphocytes ($\times 10^9$ /L)	1.1-3.2	≥ 1.1 v.s. < 1.1	0.293 (0.068-1.266)	0.100	0.337 (0.077-1.475)	0.149
Monocytes ($\times 10^9$ /L)	0.1-0.6	≥ 0.6 v.s. < 0.6	0.179 (0.024-1.335)	0.179	0.182 (0.024-1.366)	0.098
Platelets ($\times 10^9$ /L)	125.0-350.0	≥ 125.0 v.s. < 125.0	0.733 (0.245-2.192)	0.578	0.837 (0.275-2.553)	0.755
Haemoglobin (g/L)	130.0-175.0	≥ 130.0 v.s. < 130.0	0.865 (0.354-2.116)	0.751	0.652 (0.244-1.732)	0.394
CD4+ T cells (%)	25.34-51.37	≥ 51.37 v.s. < 51.37	1.144 (0.439-2.980)	0.783	1.235 (0.468-3.259)	0.670
CD8+ T cells (%)	14.23-38.95	≥ 14.23 v.s. < 14.23	0.687 (0.249-1.890)	0.467	0.867 (0.303-2.482)	0.790
Coagulation function						
Prothrombin time (s)	11.0-16.0	≥ 13.5 v.s. < 13.5	1.574 (0.644-3.852)	0.320	1.112 (0.417-2.966)	0.832
Activated partial thromboplastin time (s)	28.0-43.5	≥ 43.5 v.s. < 43.5	1.363 (0.493-3.766)	0.551	1.204 (0.433-3.344)	0.722
Fibrinogen (g/L)	2.0-4.0	≥ 4.0 v.s. < 4.0	0.533 (0.212-1.338)	0.180	0.520 (0.205-1.317)	0.168
Thrombin time (s)	14.0-21.0	≥ 17.4 v.s. < 17.4	1.114 (0.463-2.678)	0.809	1.197 (0.489-2.930)	0.694
D-dimer (mg/L)	< 0.5	≥ 0.5 v.s. < 0.5	1.232 (0.411-3.697)	0.710	0.940 (0.294-3.001)	0.917
Biochemical						
Alanine aminotransferase (U/L)	5-40	≥ 40 v.s. < 40	0.961 (0.393-2.351)	0.931	1.203 (0.429-3.373)	0.726
Aspartate aminotransferase (U/L)	8-40	≥ 40 v.s. < 40	1.611 (0.658-3.942)	0.296	1.900 (0.755-4.783)	0.173
Total bilirubin (μ mol/L)	5.1-19.0	≥ 19.0 v.s. < 19.0	5.849 (2.433-14.063)	< 0.001	6.171 (2.458-15.496)	< 0.001
Total protein (g/L)	60-80	≥ 60 v.s. < 60	0.687 (0.284-1.661)	0.405	0.721 (0.298-1.748)	0.470
Albumin (g/L)	35-55	≥ 35 v.s. < 35	0.054 (0.007-0.405)	0.054	0.060 (0.008-0.460)	0.007

Globulin (g/L)	20-30	≥ 30 v.s. < 30	2.723 (1.113-6.666)	0.028	2.526 (1.027-6.211)	0.043
Prealbumin (mg/L)	170-420	≥ 170 v.s. < 170	1.001 (0.364-2.755)	0.999	1.282 (0.448-3.665)	0.643
Blood urea nitrogen (mmol/L)	2.9-8.2	≥ 8.2 v.s. < 8.2	6.283 (2.565-15.391)	< 0.001	5.640 (2.193-14.509)	< 0.001
Creatinine (μmol/L)	44-133	≥ 74 v.s. < 74	0.973 (0.405-2.337)	0.950	0.709 (0.254-1.978)	0.511
Creatine kinase (U/L)	38-174	≥ 174 v.s. < 174	2.039 (0.783-5.307)	0.144	1.982 (0.756-5.199)	0.164
Creatine kinase-MB (U/L)	0-24	≥ 24 v.s. < 24	2.449 (1.000-5.997)	0.050	3.032 (1.203-7.644)	0.019
Lactate dehydrogenase (U/L)	109-245	≥ 245 v.s. < 245	3.963 (0.915-17.161)	0.066	4.607 (1.057-20.090)	0.042
Hypersensitive cardiac troponin I (ng/L)	< 26.2	≥ 26.2 v.s. < 26.2	5.613 (2.233-14.112)	< 0.001	5.023 (1.921-13.136)	0.001
Glucose (mmol/L)	3.9-6.1	≥ 6.1 v.s. < 6.1	1.678 (0.637-4.416)	0.295	1.454 (0.543-3.893)	0.457
Serum potassium (mmol/L)	3.5-5.2	≥ 4.0 v.s. < 4.0	1.112 (0.462-2.677)	0.813	0.921 (0.368-2.304)	0.860
Serum sodium (mmol/L)	136-145	≥ 136 v.s. < 136	1.881 (0.436-8.120)	0.397	3.302 (0.702-15.535)	0.131
Serum calcium (mmol/L)	2.03-2.54	≥ 2.03 v.s. < 2.03	0.385 (0.160-0.925)	0.033	0.433 (0.173-1.083)	0.073
Serum phosphorus (mmol/L)	0.96-1.62	≥ 0.96 v.s. < 0.96	0.831 (0.345-2.001)	0.680	0.794 (0.330-1.914)	0.608
Serum chlorine (mmol/L)	96-108	≥ 96 v.s. < 96	1.617 (0.375-6.970)	0.519	2.195 (0.489-9.845)	0.305
Lactate concentration (mmol/L)	0.5-1.6	≥ 1.6 v.s. < 1.6	15.457 (2.067-115.615)	0.008	15.721 (2.099-117.777)	0.007
Positive Urinary protein	/	/	3.239 (1.244-8.433)	0.016	2.905 (1.099-7.678)	0.032
Positive Urinary glucose	/	/	0.893 (0.120-6.676)	0.912	0.961 (0.128-7.238)	0.969
Positive urinary occult blood	/	/	2.474 (1.030-5.945)	0.043	2.247 (0.932-5.421)	0.071
Blood gas characteristics						
pH	7.35-7.45	≥ 7.35 v.s. < 7.35	0.427 (0.170-1.074)	0.071	0.468 (0.181-1.207)	0.116
Arterial partial pressure of oxygen (mm Hg)	80-100	≥ 80 v.s. < 80	0.295 (0.098-0.883)	0.029	0.321 (0.106-0.973)	0.045
Arterial partial pressure of carbon dioxide (mm Hg)	35-45	≥ 45 v.s. < 45	2.159 (0.892-5.230)	0.088	2.224 (0.895-5.525)	0.085

Infection-related biomarkers						
Interleukin-2 (pg/mL)	0.1-4.1	≥ 4.1 v.s. < 4.1	1.820 (0.533-6.212)	0.339	2.343 (0.654-8.389)	0.191
Interleukin-4 (pg/mL)	0.1-3.2	≥ 3.2 v.s. < 3.2	1.663 (0.663-4.172)	0.279	2.112 (0.797-5.597)	0.133
Interleukin-6 (pg/mL)	0.1-2.9	≥ 23.3 v.s. < 23.3	1.782 (0.711-4.468)	0.218	1.485 (0.575-3.836)	0.414
Interleukin-10 (pg/mL)	0.1-5.0	≥ 5.0 v.s. < 5.0	2.629 (1.010-6.843)	0.048	3.551 (1.280-9.857)	0.015
Tumour necrosis factor- α (pg/mL)	0.1-23.0	≥ 2.6 v.s. < 2.6	1.079 (0.448-2.600)	0.866	1.032 (0.427-2.491)	0.945
Interferon- γ (pg/mL)	0.1-18.0	≥ 2.5 v.s. < 2.5	1.260 (0.522-3.043)	0.607	1.421 (0.582-3.473)	0.440
C-reactive protein (mg/L)	< 8.0	≥ 65.0 v.s. < 65.0	4.703 (1.374-16.093)	0.014	5.275 (1.517-18.344)	0.009
Ferritin (ng/mL)	4.6-204.0	≥ 204.0 v.s. < 204.0	2.582 (0.210-11.930)	0.657	2.647 (0.311-22.522)	0.373

*Adjustments were made for age and sex.

†Cut points of levels were determined according to normal range, actual distribution and clinical significance.

